The strong preclinical efficacy and safety data for EDIT-401 de-risk the program and support progression toward an IND/CTA filing. Traders should watch for regulatory submission announcements and potential partnership interest in the cardiovascular gene editing space. The stock may see positive momentum on the data readout, but clinical-stage biotech risk remains high.
Price Chart
Executive Summary
Editas Medicine reported new preclinical data for EDIT-401, its lead in vivo gene editing candidate for hyperlipidemia, at the ASGCT 2026 Annual Meeting. A single dose achieved 90% mean LDL-C reduction across all dose groups in non-human primates, with durability through 6 months and a promising safety profile. The data supports advancement toward first-in-human clinical development but remains preclinical, with no financial or regulatory catalysts announced.
Key Facts
- Single dose of EDIT-401 achieved 90% mean LDL-C reduction across all dose groups in non-human primates.
- LDL-C reduction was durable through 6 months at evaluated dose levels (1.5 mg/kg-3.0 mg/kg).
- No adverse clinical observations at the therapeutically relevant dose (1.5 mg/kg).
- Undetectable oocyte delivery observed, suggesting favorable off-target tissue profile.
- Data support that dose adjustments may not be needed for HeFH patients based on mouse model results.
- EDIT-401 is Editas' lead in vivo development candidate for hyperlipidemia.
Financial Impact
No financial figures reported; preclinical data readout with no revenue or cost impact disclosed.
Risk Factors
- Preclinical data may not translate to human clinical trials.
- No timeline provided for first-in-human study initiation.
- Editas has no approved products and relies on future financing for operations.
- Competition from other gene editing and lipid-lowering therapies (e.g., PCSK9 inhibitors, other CRISPR programs).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001650664-26-000049 |
| Document: edit-20260514.htm | 0001650664-26-000049 |
| Document: 0001650664-26-000049-index-headers.html | 0001650664-26-000049 |
| Document: 0001650664-26-000049-index.html | 0001650664-26-000049 |
| Document: 0001650664-26-000049.txt | 0001650664-26-000049 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 8-K | $2.84 | awaiting T+20 | — | $2.40 (−15.49%) |
Sep 9, 2026 6w ago | EFFECT | $2.77 $2.75 | ▼ −0.72% | ▼ −2.92% | $2.40 (−13.36%) |
Jun 11, 2026 19w ago | Institutional Cluster | $2.44 $3.30 | ▲ +35.25% | ▲ +33.35% | $2.40 (−1.64%) |
May 26, 2026 21w ago | 424B5 | $3.57 $2.74 | ▲ +23.25% | ▲ +21.35% | $2.40 (+32.77%) |
May 26, 2026 21w ago | 8-K | $3.57 $2.74 | ▲ +23.25% | ▲ +21.35% | $2.40 (+32.77%) |
May 26, 2026 21w ago | Press Release | $3.08 $2.83 | ▲ +8.12% | ▲ +6.17% | $2.40 (+22.08%) |
May 26, 2026 21w ago | 8-K | $3.08 $2.83 | ▼ −8.12% | ▼ −6.17% | $2.40 (−22.08%) |
May 26, 2026 21w ago | 424B5 | $3.08 $2.83 | ▲ +8.12% | ▲ +6.17% | $2.40 (+22.08%) |
May 26, 2026 21w ago | Press Release | $3.08 $2.83 | ▲ +8.12% | ▲ +6.17% | $2.40 (+22.08%) |
May 26, 2026 21w ago | Press Release | $3.08 $2.83 | ▼ −8.12% | ▼ −6.17% | $2.40 (−22.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers